Base editing, a new form of gene therapy, sharply lowers bad cholesterol in clinical trial
By Jocelyn Kaiser,
Science
| 11. 12. 2023
A technique for precisely rewriting the genetic code directly in the body has slashed “bad” cholesterol levels—possibly for life—in three people prone to dangerously high levels of the artery-clogging fat. The feat relied on a blood infusion of a so-called base editor, designed to disable a liver protein, PCSK9, that regulates cholesterol.
“It is a breakthrough to have shown in humans that in vivo base editing works efficiently in the liver,” says Gerald Schwank, a gene-editing researcher at the University of Zurich who wasn’t involved in the clinical trial, sponsored by the biotech Verve Therapeutics. The approach is more precise, and possibly safer, than disrupting a gene with CRISPR, the gene-editing tool from which base editing is derived.
Reported today at the American Heart Association meeting in Philadelphia, the results mark the first time this CRISPR variant has been infused into people to treat a disease. The success is also a proof of principle for using gene editing for a common health problem like high cholesterol rather than a rare disease. Verve hopes its base editor could eventually be a...
Related Articles
By Hannah Devlin, The Guardian | 05.14.2024
Photo by Kind and Curious from Unsplash
When Great Ormond Street hospital (Gosh) published the results of its gene therapy trial for “bubble baby” syndrome it was hailed as a medical breakthrough. The treatment had a more than 95% success...
By Victoria Bisset and Adela Suliman, The Washington Post | 05.09.2024
Photo by CDC from Unsplash
A baby girl born with profound genetic deafness can now hear unaided after receiving a “groundbreaking” gene therapy trial, Britain’s National Health Service said Thursday.
Opal Sandy, an 18-month-old from Oxfordshire, England, is the first...
By Carrie Arnold, Nature Biotechnology | 04.17.2024
Tome Biosciences came out of stealth mode on 12 December with a haul of over $200 million to develop the company’s gene editing platform. Tome’s first order of business was to snap up Replace Therapeutics to expand its toolkit to...
By Rob Stein, NPR | 04.24.2024
Lisa Pisano was lying in a hospital bed at NYU Langone Health, hooked up to beeping monitors and an array of tubes. Her surgical wounds were still healing, and she looked tired. But the 54-year-old New Jersey woman said she...